Recall: D-0492-2017

Class II - Potentially Harmful

Class IIClassification

2017-01-19Initiated

TerminatedStatus

Mylan Pharmaceuticals Inc.Firm

Product

Mirtazapine Tablets, USP 45 mg, a) 30 count, b) 100 count and c) 500 count bottles, Rx only, Mylan Pharmaceuticals Inc., Morgantown, WV

Reason

Presence of Foreign Tablets/Capsules; possibility of Glipizide 10 mg tablet in bottle

Distribution

Nationwide

Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.